According to the company, VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg.
Viridian Therapeutics Inc. announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), in patients with chronic thyroid eye disease (TED).
In a news release, the company also announced an amendment to its ongoing THRIVE Phase 3 trial design and provided an update on recent progress of its SC program candidates in TED.
Kimberly Cockerham, MD, an oculoplastic Surgeon specializing in neuro-ophthalmology, orbital oncology and oculofacial restoration at the SENTA Clinic in San Diego, California, and an investigator on the VRDN-001 clinical trial, pointed out patients in the 10 mg/kg and 3 mg/kg dose cohorts experienced reductions in proptosis as well as improvements in their clinical activity scores after receiving just two infusions of VRDN-001.
“Importantly, VRDN-001 was generally well tolerated among all treated patients, who will continue to be evaluated for safety and durability of response,” she said in the news release. “Thus far, these data suggest that VRDN-001 has the potential to become an important new treatment option for managing the signs and symptoms of TED.”
According to the news release, the proof-of-concept portion of the double-masked, placebo-controlled Phase 1/2 trial evaluated two infusions of VRDN-001 administered intravenously (IV), three weeks apart, with clinical activity endpoints measured six weeks after the first infusion. VRDN-001 was evaluated at doses of 10 and 3 mg/kg, with each cohort designed to include six patients randomized to drug, and two patients randomized to placebo.
The company noted in its release that the eligibility of participants was determined by criteria that included chronic TED with documented evidence of ocular symptoms or signs that began more than one year prior to screening (mean duration of 7.8 years), and proptosis of ≥3 mm above normal values for gender and race. Any clinical activity score (CAS, 0 – 7) was allowed for randomization (mean CAS was 3.3).
According to the news release, VRDN-001 was generally well tolerated by all drug treated patients in both dose cohorts. The trial found no reported serious adverse events (SAEs), including no hearing impairment or hyperglycemia events, in patients with chronic TED treated with VRDN-001 as of May 30, 2023, the most recent cutoff date for follow-up observation.
Moreover, the company noted the safety and tolerability profile was generally consistent with previously reported results in patients with active TED treated with VRDN-001.
The company noted patients in the 10 mg/kg (n=6) and 3 mg/kg (n=6) cohorts who were treated with two doses of VRDN-001 were evaluated for changes in proptosis, CAS, and diplopia at week 6. In the study, proptosis changes from baseline were measured both by exophthalmometry and magnetic resonance imaging (MRI).
“We believe exophthalmometry and MRI together provide a robust assessment of changes in proptosis,” the company said in its news release.
The clinical trial did find that 5 out of the 12 VRDN-001 treated patients across both dose cohorts had diplopia (double vision) at baseline. None of the patients treated with VRDN-001 achieved complete resolution of diplopia at week 6, defined as patients with baseline diplopia who achieved a score of 0 on the Gorman subjective diplopia scale.
Barrett Katz, MD, MBA, chief medical officer at Viridian, the company is enthused over the clinical trial data it is compiling on VRDN-001.
“As shown previously in our proof-of-concept study in patients with active TED, and now in those with chronic disease, VRDN-001 appears to be generally well tolerated and shows clinically meaningful changes, making it a promising lead candidate in our mission to develop therapies to improve the lives of those with TED,” Katz said in the news release.
The company noted that on the heels of recent discussions with the FDA regarding Viridian’s proposal to amend the THRIVE Phase 3 trial design, THRIVE will now include the VRDN-001 5-dose treatment regimen and placebo arms only.
“The trial design amendment reflects Viridian’s confidence in the 5-dose treatment regimen of VRDN-001 and takes into consideration key stakeholder feedback from the TED community expressing preference for a shortened treatment regimen compared to an 8-dose treatment regimen,” the company said in its news release.
According to the company, the key efficacy endpoint for THRIVE, proptosis responder rate, will be evaluated at week 15. The company said in its news release it expects to announce topline results from the THRIVE Phase 3 trial in the middle of 2024.
Viridian plans to initiate the THRIVE-2 Phase 3 trial to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED in the third quarter of 2023. The Company expects to announce topline results from the THRIVE-2 trial by year-end 2024.
The company also maintains that data from the 3 mg/kg dose cohorts of VRDN-001 in patients with active or chronic TED validate a low-volume, SC product profile for the Company’s three SC candidates. The Company’s recent progress and upcoming priorities for its SC programs, include:
Viridian said in the news release it expects to select its lead subcutaneous program by year-end 2023 and to advance the program into a pivotal Phase 2/3 trial in the middle of 2024.
VRDN-001, -002, and -003 are investigational therapies that are not approved for any use in any country, the company concluded.